 "Zydus Gains FDA Approval for Scopolamine Patch, Tapping .6M Market")
Zydus Gains FDA Approval for Scopolamine Patch, Tapping $69.6M Market
Zydus Lifesciences Ltd has secured final approval from the US FDA to Market its Scopolamine transdermal system, designed to prevent nausea and vomiting in various situations, including after surgery and due to motion sickness. The product, which delivers 1 mg over 3 days, will be manufactured at Zydus’ facility in Ahmedabad. This marks the fifth ...
